Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development
Published Date:Dec 2016
Source:Drugs R D. 16(4):327-338.
Pubmed Central ID:PMC5114202
Currently available measles vaccines are administered by subcutaneous injections and require reconstitution with a diluent and a cold chain, which is resource intensive and challenging to maintain. To overcome these challenges and potentially increase vaccination coverage, microneedle patches are being developed to deliver the measles vaccine. This study compares the cost-effectiveness of using microneedle patches with traditional vaccine delivery by syringe-and-needle (subcutaneous vaccination) in children’s measles vaccination programs.
We built a simple spreadsheet model to compute the vaccination costs for using microneedle patch and syringe-and-needle technologies. We assumed that microneedle vaccines will be, compared with current vaccines, more heat stable and require less expensive cool chains when used in the field. We used historical data on the incidence of measles among communities with low measles vaccination rates.
The cost of microneedle vaccination was estimated at US$0.95 (range US$0.71–US$1.18) for the first dose, compared with US$1.65 (range US$1.24–US$2.06) for the first dose delivered by subcutaneous vaccination. At 95 % vaccination coverage, microneedle patch vaccination was estimated to cost US$1.66 per measles case averted (range US$1.24–US$2.07) compared with an estimated cost of US$2.64 per case averted (range US$1.98–US$3.30) using subcutaneous vaccination.
Use of microneedle patches may reduce costs; however, the cost-effectiveness of patches would depend on the vaccine recipients’ acceptability and vaccine effectiveness of the patches relative to the existing conventional vaccine-delivery method. This study emphasizes the need to continue research and development of this vaccine-delivery method that could boost measles elimination efforts through improved access to vaccines and increased vaccination coverage.
Electronic supplementary material
The online version of this article (doi:10.1007/s40268-016-0144-x) contains supplementary material, which is available to authorized users.
image/gif image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg application/vnd.openxmlformats-officedocument.wordprocessingml.document application/vnd.ms-excel application/octet-stream
You May Also Like: